Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,144
archived clinical trials in
Ocular

Three Month Efficacy/Safety Study With a 3 Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%
Three Month Efficacy/Safety Study With a 3 Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% Fixed Combination TID vs. Brinzolamide 1% TID or Brimonidine 0.2% TID
Status: Archived
Alcon Call Center
mi
from
Fort Worth, TX
Three Month Efficacy/Safety Study With a 3 Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%
Three Month Efficacy/Safety Study With a 3 Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% Fixed Combination TID vs. Brinzolamide 1% TID or Brimonidine 0.2% TID
Status: Archived
Updated: 1/1/1970
Alcon Call Center
mi
from
Fort Worth, TX
Efficacy and Safety Study of Brinzolamide 1% / Brimonidine 0.2% vs. Brinzolamide 1% and Brimonidine 0.2%
Efficacy and Safety Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination TID vs. Brinzolamide 1% TID and Brimonidine 0.2% TID
Status: Archived
Alcon Call Center
mi
from
Fort Worth, TX
Efficacy and Safety Study of Brinzolamide 1% / Brimonidine 0.2% vs. Brinzolamide 1% and Brimonidine 0.2%
Efficacy and Safety Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination TID vs. Brinzolamide 1% TID and Brimonidine 0.2% TID
Status: Archived
Updated: 1/1/1970
Alcon Call Center
mi
from
Fort Worth, TX
Patient Perception Study for AL-4943A
Status: Archived
Alcon Call Center
mi
from
Fort Worth, TX
Patient Perception Study for AL-4943A
Status: Archived
Updated: 1/1/1970
Alcon Call Center
mi
from
Fort Worth, TX
A Clinical Evaluation of an Investigational Lubricant Eye Gel (FID 115958D)
Status: Archived
Alcon Call Center
mi
from
Fort Worth, TX
A Clinical Evaluation of an Investigational Lubricant Eye Gel (FID 115958D)
Status: Archived
Updated: 1/1/1970
Alcon Call Center
mi
from
Fort Worth, TX
Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension
Status: Archived
Clinical Trial Facility
mi
from
Austin, TX
Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Austin, TX
Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis
Dose Ranging Study to Evaluate the Safety and Efficacy of Mapracorat Ophthalmic Formulation, in Subjects With Allergic Conjunctivitis Compared to Vehicle in a Conjunctival Allergen Challenge (CAC).
Status: Archived
Bausch & Lomb
mi
from
Rochester, NY
Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis
Dose Ranging Study to Evaluate the Safety and Efficacy of Mapracorat Ophthalmic Formulation, in Subjects With Allergic Conjunctivitis Compared to Vehicle in a Conjunctival Allergen Challenge (CAC).
Status: Archived
Updated: 1/1/1970
Bausch & Lomb
mi
from
Rochester, NY
Assessment of Alcon's Ocular Image Quantification System
Status: Archived
Alcon Call Center
mi
from
Fort Worth, TX
Assessment of Alcon's Ocular Image Quantification System
Status: Archived
Updated: 1/1/1970
Alcon Call Center
mi
from
Fort Worth, TX
Randomized Comparison of the Abbott WHITESTAR Signature System With Ellips Tranversal Ultrasound vs. the Alcon Infiniti With the Ozil Torsional Handpiece in Phacoemulsification: A Contralaterally-Controlled Trial
Randomized Comparison of the Abbott WHITESTAR Signature System With Ellips Tranversal Ultrasound vs. the Alcon Infiniti With the Ozil Torsional Handpiece in Phacoemulsification: A Contralaterally-Controlled Trial
Status: Archived
Kerry Assil
mi
from
Beverly Hills, CA
Randomized Comparison of the Abbott WHITESTAR Signature System With Ellips Tranversal Ultrasound vs. the Alcon Infiniti With the Ozil Torsional Handpiece in Phacoemulsification: A Contralaterally-Controlled Trial
Randomized Comparison of the Abbott WHITESTAR Signature System With Ellips Tranversal Ultrasound vs. the Alcon Infiniti With the Ozil Torsional Handpiece in Phacoemulsification: A Contralaterally-Controlled Trial
Status: Archived
Updated: 1/1/1970
Kerry Assil
mi
from
Beverly Hills, CA
Evaluation of Anti-inflammatory Treatment in Dry Eye Patients
Status: Archived
Alcon Call Center
mi
from
Fort Worth, TX
Evaluation of Anti-inflammatory Treatment in Dry Eye Patients
Status: Archived
Updated: 1/1/1970
Alcon Call Center
mi
from
Fort Worth, TX
A Single-Center, Randomized, Double-Masked, Placebo and Active Controlled, Dose-Ranging Evaluation of the Duration of Action of Brimonidine Tartrate Ophthalmic Solution in the Control of Ocular Redness Induced by Conjunctival Allergen Challenge (CAC)
A Single-Center, Randomized, Double-Masked, Placebo and Active Controlled, Dose-Ranging Evaluation of the Duration of Action of Brimonidine Tartrate Ophthalmic Solution in the Control of Ocular Redness Induced by Conjunctival Allergen Challenge (CAC)
Status: Archived
ORA Inc
mi
from
Andover, MA
A Single-Center, Randomized, Double-Masked, Placebo and Active Controlled, Dose-Ranging Evaluation of the Duration of Action of Brimonidine Tartrate Ophthalmic Solution in the Control of Ocular Redness Induced by Conjunctival Allergen Challenge (CAC)
A Single-Center, Randomized, Double-Masked, Placebo and Active Controlled, Dose-Ranging Evaluation of the Duration of Action of Brimonidine Tartrate Ophthalmic Solution in the Control of Ocular Redness Induced by Conjunctival Allergen Challenge (CAC)
Status: Archived
Updated: 1/1/1970
ORA Inc
mi
from
Andover, MA
A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis
Status: Archived
Alcon Call Center
mi
from
Fort Worth, TX
A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis
Status: Archived
Updated: 1/1/1970
Alcon Call Center
mi
from
Fort Worth, TX
A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Vehicle in Subjects With Blepharitis
A Randomized, Multi-Center, Double-Masked, Vehicle-Controlled, Parallel-Group, Safety and Efficacy Study of Azithromycin Ophthalmic Solution, 1% Versus Vehicle for Four Weeks in Subjects With Blepharitis
Status: Archived
Sall Research Medical Center
mi
from
Downey-Norwalk, CA
A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Vehicle in Subjects With Blepharitis
A Randomized, Multi-Center, Double-Masked, Vehicle-Controlled, Parallel-Group, Safety and Efficacy Study of Azithromycin Ophthalmic Solution, 1% Versus Vehicle for Four Weeks in Subjects With Blepharitis
Status: Archived
Updated: 1/1/1970
Sall Research Medical Center
mi
from
Downey-Norwalk, CA
A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Vehicle in Subjects With Blepharitis
A Randomized, Multi-Center, Double-Masked, Vehicle-Controlled, Parallel-Group, Safety and Efficacy Study of Azithromycin Ophthalmic Solution, 1% Versus Vehicle for Four Weeks in Subjects With Blepharitis
Status: Archived
Wolstan & Goldberg Eye Associates
mi
from
Torrence, CA
A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Vehicle in Subjects With Blepharitis
A Randomized, Multi-Center, Double-Masked, Vehicle-Controlled, Parallel-Group, Safety and Efficacy Study of Azithromycin Ophthalmic Solution, 1% Versus Vehicle for Four Weeks in Subjects With Blepharitis
Status: Archived
Updated: 1/1/1970
Wolstan & Goldberg Eye Associates
mi
from
Torrence, CA
A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Vehicle in Subjects With Blepharitis
A Randomized, Multi-Center, Double-Masked, Vehicle-Controlled, Parallel-Group, Safety and Efficacy Study of Azithromycin Ophthalmic Solution, 1% Versus Vehicle for Four Weeks in Subjects With Blepharitis
Status: Archived
Tauber Eye Center
mi
from
Kansas City, MO
A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Vehicle in Subjects With Blepharitis
A Randomized, Multi-Center, Double-Masked, Vehicle-Controlled, Parallel-Group, Safety and Efficacy Study of Azithromycin Ophthalmic Solution, 1% Versus Vehicle for Four Weeks in Subjects With Blepharitis
Status: Archived
Updated: 1/1/1970
Tauber Eye Center
mi
from
Kansas City, MO
A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Vehicle in Subjects With Blepharitis
A Randomized, Multi-Center, Double-Masked, Vehicle-Controlled, Parallel-Group, Safety and Efficacy Study of Azithromycin Ophthalmic Solution, 1% Versus Vehicle for Four Weeks in Subjects With Blepharitis
Status: Archived
Comprehensive Eye Care
mi
from
St Louis, MO
A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Vehicle in Subjects With Blepharitis
A Randomized, Multi-Center, Double-Masked, Vehicle-Controlled, Parallel-Group, Safety and Efficacy Study of Azithromycin Ophthalmic Solution, 1% Versus Vehicle for Four Weeks in Subjects With Blepharitis
Status: Archived
Updated: 1/1/1970
Comprehensive Eye Care
mi
from
St Louis, MO
A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Vehicle in Subjects With Blepharitis
A Randomized, Multi-Center, Double-Masked, Vehicle-Controlled, Parallel-Group, Safety and Efficacy Study of Azithromycin Ophthalmic Solution, 1% Versus Vehicle for Four Weeks in Subjects With Blepharitis
Status: Archived
Abrams Eye Institute
mi
from
Las Vegas, NV
A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Vehicle in Subjects With Blepharitis
A Randomized, Multi-Center, Double-Masked, Vehicle-Controlled, Parallel-Group, Safety and Efficacy Study of Azithromycin Ophthalmic Solution, 1% Versus Vehicle for Four Weeks in Subjects With Blepharitis
Status: Archived
Updated: 1/1/1970
Abrams Eye Institute
mi
from
Las Vegas, NV
A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Vehicle in Subjects With Blepharitis
A Randomized, Multi-Center, Double-Masked, Vehicle-Controlled, Parallel-Group, Safety and Efficacy Study of Azithromycin Ophthalmic Solution, 1% Versus Vehicle for Four Weeks in Subjects With Blepharitis
Status: Archived
Abrams Eye Center
mi
from
Cleveland, OH
A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Vehicle in Subjects With Blepharitis
A Randomized, Multi-Center, Double-Masked, Vehicle-Controlled, Parallel-Group, Safety and Efficacy Study of Azithromycin Ophthalmic Solution, 1% Versus Vehicle for Four Weeks in Subjects With Blepharitis
Status: Archived
Updated: 1/1/1970
Abrams Eye Center
mi
from
Cleveland, OH
A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Vehicle in Subjects With Blepharitis
A Randomized, Multi-Center, Double-Masked, Vehicle-Controlled, Parallel-Group, Safety and Efficacy Study of Azithromycin Ophthalmic Solution, 1% Versus Vehicle for Four Weeks in Subjects With Blepharitis
Status: Archived
University Eye Surgeons
mi
from
Maryville, TN
A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Vehicle in Subjects With Blepharitis
A Randomized, Multi-Center, Double-Masked, Vehicle-Controlled, Parallel-Group, Safety and Efficacy Study of Azithromycin Ophthalmic Solution, 1% Versus Vehicle for Four Weeks in Subjects With Blepharitis
Status: Archived
Updated: 1/1/1970
University Eye Surgeons
mi
from
Maryville, TN
Proparacaine and Mydriatic Eye Drops
Randomized Control Trial of the Effects of Proparacaine on the Pain Response to Mydriatic Eye Drops
Status: Archived
University of Pennsylvania, Pennsylvania Hospital Department of Neurology , 330 South 9Th Street
mi
from
Philadelphia, PA
Proparacaine and Mydriatic Eye Drops
Randomized Control Trial of the Effects of Proparacaine on the Pain Response to Mydriatic Eye Drops
Status: Archived
Updated: 1/1/1970
University of Pennsylvania, Pennsylvania Hospital Department of Neurology , 330 South 9Th Street
mi
from
Philadelphia, PA
Lucentis in Advanced Macular Degeneration
Lucentis in Advanced Macular Degeneration
Status: Archived
California Pacific Medical Center
mi
from
San Francisco, CA
Lucentis in Advanced Macular Degeneration
Lucentis in Advanced Macular Degeneration
Status: Archived
Updated: 1/1/1970
California Pacific Medical Center
mi
from
San Francisco, CA
Lucentis in Advanced Macular Degeneration
Lucentis in Advanced Macular Degeneration
Status: Archived
Stanford university Hospital and Clinics
mi
from
Stanford, CA
Lucentis in Advanced Macular Degeneration
Lucentis in Advanced Macular Degeneration
Status: Archived
Updated: 1/1/1970
Stanford university Hospital and Clinics
mi
from
Stanford, CA
The Use of Transcranial Direct Current Stimulation (TDCS) to Enhance the Rehabilitative Effect of Vision Restoration Therapy
Status: Archived
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
The Use of Transcranial Direct Current Stimulation (TDCS) to Enhance the Rehabilitative Effect of Vision Restoration Therapy
Status: Archived
Updated: 1/1/1970
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
The Use of Transcranial Direct Current Stimulation (TDCS) to Enhance the Rehabilitative Effect of Vision Restoration Therapy
Status: Archived
Massachusetts General Hospital
mi
from
Boston, MA
The Use of Transcranial Direct Current Stimulation (TDCS) to Enhance the Rehabilitative Effect of Vision Restoration Therapy
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
mi
from
Boston, MA
Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD)
Eculizumab for the Treatment of Non-Exudative Age-Related Macular Degeneration: An Exploratory Study to Evaluate the Effects of C5 Inhibition on Drusen and Geographic Atrophy
Status: Archived
Bascom Palmer Eye Institute
mi
from
Miami, FL
Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD)
Eculizumab for the Treatment of Non-Exudative Age-Related Macular Degeneration: An Exploratory Study to Evaluate the Effects of C5 Inhibition on Drusen and Geographic Atrophy
Status: Archived
Updated: 1/1/1970
Bascom Palmer Eye Institute
mi
from
Miami, FL
Macular Edema Incidence/Severity Reduction With Nevanac
Status: Archived
Alcon Call Center
mi
from
Fort Worth, TX
Macular Edema Incidence/Severity Reduction With Nevanac
Status: Archived
Updated: 1/1/1970
Alcon Call Center
mi
from
Fort Worth, TX
Evaluation of Safety of Latanoprost Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension
A Clinical Evaluation of Safety of Latanoprost Ophthalmic Solution When Administered Once Daily in Subjects With Open Angle Glaucoma or Ocular Hypertension: an Open Label Study
Status: Archived
Cornerstone Eye Care
mi
from
High Point, NC
Evaluation of Safety of Latanoprost Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension
A Clinical Evaluation of Safety of Latanoprost Ophthalmic Solution When Administered Once Daily in Subjects With Open Angle Glaucoma or Ocular Hypertension: an Open Label Study
Status: Archived
Updated: 1/1/1970
Cornerstone Eye Care
mi
from
High Point, NC
Efficacy and Safety of 2 Formulations of Latanoprost Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension
Comparison of the Efficacy and Safety of 2 Formulations of Latanoprost Ophthalmic Solution When Administered Once Daily in Subjects With Open Angle Glaucoma or Ocular Hypertension
Status: Archived
David Shulman
mi
from
San Antonio, TX
Efficacy and Safety of 2 Formulations of Latanoprost Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension
Comparison of the Efficacy and Safety of 2 Formulations of Latanoprost Ophthalmic Solution When Administered Once Daily in Subjects With Open Angle Glaucoma or Ocular Hypertension
Status: Archived
Updated: 1/1/1970
David Shulman
mi
from
San Antonio, TX
Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Uveitic Macular Edema
Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Uveitic Macular Edema
Status: Archived
Department of Ophthalmology, Mount Sinai School of Medicine
mi
from
New York, NY
Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Uveitic Macular Edema
Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Uveitic Macular Edema
Status: Archived
Updated: 1/1/1970
Department of Ophthalmology, Mount Sinai School of Medicine
mi
from
New York, NY
Efficacy and Safety of Adding Azarga to Prostaglandin Monotherapy
Status: Archived
Alcon Call Center
mi
from
Fort Worth, TX
Efficacy and Safety of Adding Azarga to Prostaglandin Monotherapy
Status: Archived
Updated: 1/1/1970
Alcon Call Center
mi
from
Fort Worth, TX
Clinical Evaluation of the Causes of Contact Lens Related Dry Eye
Status: Archived
Alcon Call Center
mi
from
Fort Worth, TX
Clinical Evaluation of the Causes of Contact Lens Related Dry Eye
Status: Archived
Updated: 1/1/1970
Alcon Call Center
mi
from
Fort Worth, TX
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Retinal Consultants of AZ
mi
from
Phoenix, AZ
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Retinal Consultants of AZ
mi
from
Phoenix, AZ
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
University of California, Irvine
mi
from
Irvine, CA
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
University of California, Irvine
mi
from
Irvine, CA
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Loma Linda University Health Care, Dept. of Ophthalmology
mi
from
Loma Linda, CA
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Loma Linda University Health Care, Dept. of Ophthalmology
mi
from
Loma Linda, CA
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Southern California Desert Retina Consultants, MC
mi
from
Palm Springs, CA
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Southern California Desert Retina Consultants, MC
mi
from
Palm Springs, CA
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Bay Area Retina Associates
mi
from
Castro Valley, CA
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Bay Area Retina Associates
mi
from
Castro Valley, CA
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Retinal Consultants of Southern California Medical Group, Inc.
mi
from
Westlake Village, CA
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Retinal Consultants of Southern California Medical Group, Inc.
mi
from
Westlake Village, CA
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Denver Health Medical Center
mi
from
Denver, CO
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Denver Health Medical Center
mi
from
Denver, CO
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
New England Retina Associates, PC
mi
from
Trumbull, CT
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
New England Retina Associates, PC
mi
from
Trumbull, CT
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
The George Washington University, Department of Ophthalmology
mi
from
Washington,
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
The George Washington University, Department of Ophthalmology
mi
from
Washington,
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Retina Consultants of Southwest Florida
mi
from
Fort Myers, FL
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Retina Consultants of Southwest Florida
mi
from
Fort Myers, FL
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
University of Florida College of Med., Department of Ophthalmology
mi
from
Jacksonville, FL
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
University of Florida College of Med., Department of Ophthalmology
mi
from
Jacksonville, FL
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Florida Retina Consultants
mi
from
Lakeland, FL
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Florida Retina Consultants
mi
from
Lakeland, FL
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Magruder Eye Institute
mi
from
Orlando, FL
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Magruder Eye Institute
mi
from
Orlando, FL
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Sarasota Retina Institute
mi
from
Sarasota, FL
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Sarasota Retina Institute
mi
from
Sarasota, FL
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Retina Associates of Sarasota
mi
from
Venice, FL
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Retina Associates of Sarasota
mi
from
Venice, FL
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Emory Eye Center
mi
from
Atlanta, GA
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Emory Eye Center
mi
from
Atlanta, GA
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Georgia Retina, P.C.
mi
from
Decatur, GA
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Georgia Retina, P.C.
mi
from
Decatur, GA
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Southeast Retina Center, P.C.
mi
from
Augusta, GA
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Southeast Retina Center, P.C.
mi
from
Augusta, GA
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Retina Associates of Hawaii, Inc.
mi
from
Honolulu, HI
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
Retina Associates of Hawaii, Inc.
mi
from
Honolulu, HI
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
University of Illinois at Chicago Medical Center
mi
from
Chicago, IL
Intravitreal Ranibizumab for VH Due to PDR (N)
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Status: Archived
Updated: 1/1/1970
University of Illinois at Chicago Medical Center
mi
from
Chicago, IL